Research Topics
Species | Frank PajonkSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Anthracyclines, proteasome activity and multi-drug-resistanceMirela R Fekete
Department of Neurology, Bürgerhospital, Tunzhofer Str 14 16, 70191 Stuttgart, Germany
BMC Cancer 5:114. 2005..Observations that cyclosporin A, and certain other substances, inhibit both the proteasome and P-glycoprotein led us to investigate whether anthracyclines, well known substrates of P-gp, also inhibit the function of the proteasome...- Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisitedFrank Pajonk
Department of Radiation Oncology, Division of Molecular and Cellular Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Stem Cells 28:639-48. 2010..We relate recent findings on CSCs to these four phenomena and discuss possible consequences... - The effects of tea extracts on proinflammatory signalingFrank Pajonk
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
BMC Med 4:28. 2006..We investigated the underlying molecular mechanisms and compared effects of tea extracts with the effects of epigallocatechin-gallate, the proposed most-active moiety of green tea... - The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiationFrank Pajonk
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
Neoplasia 8:1037-41. 2006..This study was designed to determine how varying cycles of hypoxia/reoxygenation affect the response of cervical carcinoma cells irradiated under oxic and hypoxic conditions and whether this could be modulated by proteasome inhibition... - Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatmentChann Lagadec
Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1714, USA
Breast Cancer Res 12:R13. 2010..We hypothesized that CICs, in contrast to their non-tumorigenic counterparts, not only survive fractions of ionizing radiation but also retain the CIC phenotype as defined by operational means... - The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanismFrank Pajonk
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA90095 1714, USA
BMC Cancer 5:76. 2005.... - Radioresistance of prostate cancer cells with low proteasome activityLorenza Della Donna
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, Los Angeles, CA 90095 1714, USA
Prostate 72:868-74. 2012..Proteasome inhibitors have been suggested as promising new agents against solid tumors including prostate cancer but initial results from clinical trials are disappointing... - In vivo imaging, tracking, and targeting of cancer stem cellsErina Vlashi
Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095 1714, USA
J Natl Cancer Inst 101:350-9. 2009..The 26S proteasome is the main regulator of many processes within a proliferating cell, and its activity may be altered depending on the phenotype of a cell... - Effects of recombinant erythropoietin on breast cancer-initiating cellsTiffany M Phillips
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, 10833 LeConte Ave, Los Angeles, CA 90095 1714, USA
Neoplasia 9:1122-9. 2007..Cancer recurrence is thought to rely on the proliferation of cancer initiating cells (CICs). In breast cancer, CICs can be identified by phenotypic markers and their fate is controlled by the Notch pathway... - Metabolic state of glioma stem cells and nontumorigenic cellsErina Vlashi
Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 108:16062-7. 2011..We conclude that GSCs rely mainly on oxidative phosphorylation. However, if challenged, they can use additional metabolic pathways. Therefore, targeting glycolysis in glioma may spare GSCs... - Radiation-induced reprogramming of breast cancer cellsChann Lagadec
Department of Radiation Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1714, USA
Stem Cells 30:833-44. 2012..We conclude that radiation may induce a BCSC phenotype in differentiated breast cancer cells and that this mechanism contributes to increased BCSC numbers seen after classic anticancer treatment... - Oxygen levels do not determine radiation survival of breast cancer stem cellsChann Lagadec
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States of America
PLoS ONE 7:e34545. 2012..We conclude that because BCSCs are protected from radiation through high expression levels of free radical scavengers, hypoxia does not lead to additional radioprotection of BCSCs... 
A sense of danger from radiationWilliam H McBride
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1714, USA
Radiat Res 162:1-19. 2004..This article focuses on how normal tissues and tumors sense and respond to danger from ionizing radiation, on the nature of the signals that are sent, and on the impact on the eventual consequences of exposure...- Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma CellsErina Vlashi
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Transl Oncol 3:50-5. 2010..We conclude that NPI-0052 is not a suitable drug for the treatment of malignant gliomas despite its efficacy in other cancer types... - Radiation responses of cancer stem cellsErina Vlashi
Division of Molecular and Cellular Oncology, Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1714, USA
J Cell Biochem 108:339-42. 2009..This is particularly true for biological targeting of cancer for enhanced radiotherapeutic benefit, which must consider whether the unique properties of this subpopulation allow it to avoid such therapies... - The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiationTiffany M Phillips
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1714, USA
J Natl Cancer Inst 98:1777-85. 2006..These findings offer a possible mechanism for the accelerated repopulation of tumor cells observed during gaps in radiotherapy... - The role of the ubiquitin/proteasome system in cellular responses to radiationWilliam H McBride
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Oncogene 22:5755-73. 2003..In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective... - Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cellsFrank Pajonk
Department of Radiation Oncology, Experimental Division, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1714, USA
Cancer Res 65:4836-43. 2005..Hyperthermia abrogates AR expression in androgen-dependent cells and might thus promote malignant progression of prostate cancer... - Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant gliomaPatrick Evers
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
BMC Cancer 10:384. 2010..This suggests that the NSC niches in the brain may harbor cancer stem cells (CSCs), Thus providing novel therapy targets. We hypothesize that higher radiation doses to these NSC niches improve patient survival by eradicating CSCs... - NF-kappa B, cytokines, proteasomes, and low-dose radiation exposureWilliam H McBride
Roy E. Coats Laboratories, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90064, USA
Mil Med 167:66-7. 2002..These pathways are relevant to low-dose radiation effects, adaptive responses, and carcinogenesis... 
National institutes of health funding in radiation oncology: a snapshotMichael Steinberg
Department of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles UCLA, and Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California
Int J Radiat Oncol Biol Phys 86:234-40. 2013..Our data suggest that the field of radiation oncology is underfunded by the NIH and that the current level of support does not match the relevance of radiation oncology for cancer patients or the potential of its academic work force...- The erythropoietin-receptor pathway modulates survival of cancer cellsFrank Pajonk
Clinical and Experimental Radiation Biology Research Section, Department of Radiation Therapy, Radiological University Clinic, Robert Koch Str 3, 79106 Freiburg i Brsg, Germany
Oncogene 23:8987-91. 2004..As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers... - The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cellsFrank Pajonk
Department of Radiation Therapy, Radiological University Clinic, Hugstetter Strasse 55, 79106 Freiburg i Brsg, Germany
Cancer Res 62:5230-5. 2002..Because saquinavir induced apoptosis in human cancer cells, HIV-I protease inhibitors might become a new class of cytotoxic drugs, alone or in combination with radiation or chemotherapy... - N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activationFrank Pajonk
Department of Radiation Therapy, Radiological University Clinic Freiburg, Hugstetter Strasse 55, 79106 Freiburg im Breisgau, Germany
Free Radic Biol Med 32:536-43. 2002.... - Do erythropoietin receptors on cancer cells explain unexpected clinical findings?Michael Henke
Klinik fur Strahlenheilkunde, Universitatsklinikum, Robert Koch Strasse, 3 D 79106, Freiburg, Germany
J Clin Oncol 24:4708-13. 2006..Recent reports suggest that cancer control may worsen if erythropoietin is administered. We investigated whether erythropoietin receptor expression on cancer cells may correlate with this unexpected finding... - Vitiligo at the sites of irradiation in a patient with Hodgkin's diseaseFrank Pajonk
Department of Radiation Therapy, Radiological University Clinic, Freiburg Br, Germany
Strahlenther Onkol 178:159-62. 2002..Current hypotheses discuss autoimmune, autotoxic and neuronal mechanisms. Here we report the case of radiation-induced depigmentation of the skin of a patient with Hodgkin's disease and 25-year history of vitiligo...
Research Grants
- The 26S Proteasome in Cancer Stem CellsFrank Pajonk; Fiscal Year: 2010....